Re: Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Masterson et al. [1] have presented the third randomized controlled trial (RCT) on platelet-rich-plasma (PRP) and erectile dysfunction (ED). Men with vasculogenic ED were assigned to intracavernosal PRP injections (n = 28) or placebo (n = 33). No significant differences were noted between the arms: 58.3%, 41.7%, and 60% of the PRP group, and 53.6%, 52%, and 41.7% of the placebo group met the minimal clinically important difference (MCID) for the International Index of Erectile Function-Erectile Function (IIEF-EF) scale at 1, 3, and 6 mo, respectively. The findings are in contrast to two previous RCTs and the inconsistencies necessitate a closer examination of the studies.
Originalsprog | Engelsk |
---|---|
Tidsskrift | European Urology |
Vol/bind | 85 |
Udgave nummer | 1 |
Sider (fra-til) | 93 |
Antal sider | 1 |
ISSN | 0302-2838 |
DOI |
|
Status | Udgivet - 2024 |
ID: 382432574